<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246203</url>
  </required_header>
  <id_info>
    <org_study_id>ML40429</org_study_id>
    <nct_id>NCT04246203</nct_id>
  </id_info>
  <brief_title>Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer</brief_title>
  <acronym>PROJECTION</acronym>
  <official_title>Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, multicenter, non-interventional study in patients with resectable
      PDAC. The patients are allocated to two observation groups according preoperative presence of
      ctDNA (Group A) or absence of detectable ctDNA (Group B) as determined in a liquid biopsy.
      After successful surgery of their pancreatic tumor and completion of local histological
      evaluation, tissue samples will be analyzed with regard to their mutational status with.
      Within 14 days before start of adjuvant tumor therapy another liquid biopsy will be taken to
      reassess the level of ctDNA after surgery.

      Patients will be monitored for disease recurrence according to harmonized, institutional
      standards using clinical, laboratory and (cross-sectional) imaging modalities. Accordingly,
      patients will be assessed every three months in the first eighteen months after surgery and
      every six months thereafter or based on clinical need for 36 months after the date of surgery
      Follow up will be documented until occurrence of relapse (or death if death occurs earlier
      than relapse/progression) for a maximum of 36 months after the date of surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>Follow up will be 36 months after surgery.</time_frame>
    <description>Comparison of disease-free survival (DFS) of patients with preoperative presence of ctDNA (Group A) and absence of ctDNA (Group B)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients are allocated to group A according to preoperative presence of detectable ctDNA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients are allocated to group B according to preoperative absence of detectable ctDNA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Liquid Biopsy</intervention_name>
    <description>17-20 ml of blood will be collected prior of surgery and within 14 days before start of adjuvant chemotherapy.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pancreatic mass, suspicious of pancreatic cancer and deemed resectable will
        be prospectively enrolled in this observational study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients ≥ 18 years of age

          2. Pancreatic mass, suspicious of pancreatic cancer, deemed resectable and resection
             planned.

          3. Patient deemed medically fit for adjuvant chemotherapy by the investigator

          4. Patient's legal capacity to consent to study participation

          5. Signed and dated informed consent to participate in the study

        Exclusion Criteria:

          1. Non-resectable disease as determined by a local tumor board

          2. Metastatic pancreatic disease

          3. Previous neoadjuvant chemotherapy

          4. Previous neoadjuvant radiotherapy

          5. Histology other than PDAC such as acinar, neuroendocrine, mixed histology etc. in the
             resection specimen

          6. Malignant disease other than PDAC within previous year (exception: patients with
             adequately treated and completely resected basal cell or squamous cell skin cancer; in
             situ cervical, breast or prostate cancer within previous year may be included)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Benedikt Westphalen</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMU Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benedikt Westphalen, MD</last_name>
    <phone>0049894400</phone>
    <phone_ext>75250</phone_ext>
    <email>cwestpha@med.lmu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bernhard W. Renz, MD</last_name>
    <phone>0049894400</phone>
    <phone_ext>0</phone_ext>
    <email>Bernhard.Renz@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Uwe Pelzer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Dirk Waldschmidt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Marianne Sinn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>Munich</city>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Quante, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Seufferlein, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 26, 2020</study_first_submitted>
  <study_first_submitted_qc>January 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 26, 2020</last_update_submitted>
  <last_update_submitted_qc>January 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Benedikt Westphalen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

